Taking Marijuana In Another Direction – Kalytera Therapeutics

Note: Please keep in mind that Kalytera is an early development stage company and still quite speculative. Companies like this should only represent a small portion of your portfolio.

It seems like a no-brainer.There are hardly any states in which the use of marijuana is legal.Over time it seems highly likely (to this investor at least) that many more if not all of the states will eventually come around.

This has to be one of the great investing opportunities of the next couple of decades.

The problem is that finding quality companies to invest in is very difficult.If you make a list of marijuana stocks to go through almost every company on the list is not something many of us would be interested in owning (putting it politely).

When you see one that is a step above the others in terms of management quality and experience it sticks out pretty clearly. Kalytera Therapeutics (TSXV:KALY) is one of those.The company is newly publicly traded having entered the market through a reverse-merger and isn’t on anyone’s radar.

Let this serve as an introduction to this company both for you and for me.

While most companies tied to marijuana have management groups that have not accomplished anything Kalytera’s CEO has a solid background. Here is his bio:

Andrew L. Salzman, M.D., Chief Executive Officer and Chief Medical Officer

Dr. Salzman is a physician, scientist, inventor, and biomedical entrepreneur. Dr. Salzman founded and built Inotek Pharmaceuticals, a 140-person biotech company that raised $92M in venture capital and concluded a $600M license with Genentech. As CEO of Inotek, Dr. Salzman brought numerous new chemical entities from conception to clinical stage testing, including a treatment for glaucoma that demonstrated clinical proof of concept in late Phase 2 clinical trials.

Dr. Salzman has been funded by the U.S. National Institutes of Health (“NIH”), authoring 75 federal grants and receiving $102 million in federal grant funding. In addition to 175 peer-reviewed scientific publications, Dr. Salzman holds 40 patents in the fields of medicine, pharmacology, organic chemistry, and medical devices.

1 2 3
View single page >> |

Disclosure: I don’t own any shares of companies mentioned in this article.

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Intelligntinvestor 3 years ago Member's comment

This #pot industry is an interesting industry to study. It would sound cool to tell your friends that you made money investing in marijuana-based companies. I’m sure that many stoners out there would love to hear about a billionaire dollar company that is working on the medical side of the pot.